Results 221 to 230 of about 135,991 (315)

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Effects of lemborexant on sleep quality and its association with morning alertness: Post hoc analysis of two phase 3 trials. [PDF]

Sleep Med X
Suzuki M, Yoshiike T, Khullar A, Kogo Y, Inabe K, Koebis M, Moline M, Cheng JY, Kumar D, Pinner K, Kuriyama K.   +10 more
europepmc   +1 more source

How to report neurotechnology and artificial intelligence studies in epilepsy: Peer‐review‐inspired recommendations

Epilepsia Open, EarlyView.
Abstract Objective The integration of neurotechnology and artificial intelligence (AI) in epilepsy research has led to significant advancements in diagnosis, monitoring, and treatment. However, the impact of these innovations is often diminished by inadequate and inaccurate reporting, limiting their reproducibility and implementation.
Pedro F. Viana, Matthew McWilliam, Andrea Biondi, Jesus Servando Medel‐Matus, Naoto Kuroda, Giulia Sofia Cereda, Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development. [PDF]

ESMO Gastrointest Oncol
Okemoto D, Nakayama I, Shitara K.
europepmc   +1 more source

Perspectives on the burden of drug‐resistant epilepsy and treatment priorities: Findings from a multistakeholder survey

Epilepsia Open, EarlyView.
Abstract Objective Drug‐resistant epilepsy (DRE) imposes a significant burden on patients and their caregivers. This study aimed to explore the concerns and perceptions of healthcare providers (HCPs), patients, and caregivers regarding the burden of disease and quality of life (QoL) in patients with DRE.
Simona Lattanzi, Bettina Schmitz, Nuno Canas, John Paul Leach, Caroline Benoist, Daniela Pierucci, Elena Álvarez‐Barón   +6 more
wiley   +1 more source

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis. [PDF]

Res Pract Thromb Haemost
Shima M, Takedani H, Kitsukawa K, Taki M, Ishiguro A, Nagae C, Nagao A, Nosaka D, Kyogoku Y, Oki H, Iwasaki K, Nogami K.   +11 more
europepmc   +1 more source

The Global Epilepsy Needs Study (GENS): A mixed‐methods, multi‐country exploration of the unmet psychosocial and everyday needs of people with epilepsy

Epilepsia Open, EarlyView.
Abstract Objective While epilepsy research has largely focused on medical management and clinical outcomes, less attention has been given to the unmet psychosocial and everyday needs of people with epilepsy (PWE), particularly in low‐ and middle‐income countries.
Gus A. Baker, Sandeep Kumar Bagga, Donna Walsh, Claire Nolan, Shivani Sharma, Charlotte Hooker, Pepa Gonzalez Parrao, Francesca Sofia, J. Helen Cross, Ma. Marta Bertone, Ivana García, Adam Jallow Janneh, Alison Kukla, Elvira Vacas Montero, Ding Ding, Latica Friedrich, Lecio Figueira Pinto, Gagandeep Singh, Chahnez Charfi Triki, Leya Raj, Allan Reese, on behalf of GENS Collaborators, Naziya Anzari, Alicia Bogacz, Martin Brodie, Heather Brooks, Nicole Coulthard, Laura Dickson, Laura Maria de Figueiredo Ferreira Guilhoto, Anchor Hung, John Nute Jabang, Boram Lee, Kheng‐Seang Lim, Rebecca Lisle, Anita Mago, Sharon Mbugua, Bindu Menon, Sarah Nekesa, Youssouf Noormamode, Per Olesen, Kris Pierce, Dzenana Rustempasic, Jitendra K. Sahu, Ana Sruk, Christa Studzinski, Nirmal Surya, Maria Alice Susemihl, Laura Weidner, Samuel Wiebe, Andrea Wilkinson, Leonie Wollscheid, Ian Wong, Bernadette Zappa   +52 more
wiley   +1 more source

Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics. [PDF]

Health Econ Rev
Takahata K, Tanaka E, Sakai R, Akazawa M.   +3 more
europepmc   +1 more source

C’est What? Saisie! A Comparison of Patent Infringement Remedies Among the G7 Economic Nations [PDF]

, 2003
Coury, Larry
core   +1 more source

Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study

Epilepsia Open, EarlyView.
Abstract This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2‐q13.1 duplication or deletion syndromes (15q‐DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5
Emanuele Cerulli Irelli, Adolfo Mazzeo, Marco Perulli, Georgia Ramantani, Domenica Battaglia, Irene Bagnasco, Erica Cognolato, Pasquale Striano, Susanna Negrin, Alberto Danieli, Paolo Bonanni, Francesca F. Operto, Carlo Di Bonaventura, Antonietta Coppola, Alessandro Orsini   +14 more
wiley   +1 more source